Sickle-cell gene therapy: access is an agreement and a care pathway

Clarus Biotech Review

The CMS access model makes outcome contracting, treatment logistics, and follow-up separate milestones.

The Cell and Gene Therapy Access Model shows how an approved technology still needs an implementation architecture. In its July 2025 participation announcement, CMS reported agreements involving 33 states, the District of Columbia, and Puerto Rico. The model initially focused on sickle-cell disease and used CMS-negotiated outcomes-based agreements with manufacturers on behalf of participating Medicaid agencies. [1]

## Participation is an input, not a treatment count

A signed state agreement is a real implementation milestone. It does not tell a reader how many eligible people were referred, evaluated, treated, or followed successfully. CMS allowed state start dates between January 2025 and January 2026; a participation map should therefore retain the date and the distinction between enrollment in the model and receipt of therapy. [1,2]

## The product must reach a prepared care setting

An access plan should map referral, suitability assessment, cell collection, manufacturing coordination, conditioning, treatment, and follow-up. At each transition, a patient may need practical support as well as an authorization. The model's design includes attention to services and supports, making the surrounding care pathway part of the implementation question. [2]

## Money has several meanings

List price, negotiated rebate, net Medicaid expenditure, and the complete episode of care are different quantities. An outcomes agreement can link payment to a defined result without guaranteeing that every program reduces total spending. The CMS model is a test of access, outcomes, and cost effects; its existence should not be reported as a completed cost-effectiveness finding. [2]

## What a useful access dashboard would show

Track the eligible cohort, referral completion, time to treatment, pathway attrition, follow-up completeness, and contract-defined outcome reconciliation. Show denominators alongside counts. That dashboard would reveal whether a contracting milestone has converted into a reachable service, which is the decision that matters to patients and health-system operators.

Sources

https://www.cms.gov/newsroom/press-releases/cms-expands-access-lifesaving-gene-therapies-through-innovative-state-agreements

https://www.cms.gov/priorities/innovation/innovation-models/cgt

Original article: https://www.clarusreview.bio/articles/science-to-practical-access